Related Experiment Video
Updated: Jul 12, 2025

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
A journey to vasculopathy in systemic sclerosis: focus on haemostasis and thrombosis
Francesco Marongiu1,2, Maria Filomena Ruberto1, Silvia Marongiu3
1Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Insights
Systemic sclerosis involves endothelial dysfunction, fibrosis, and impaired blood vessel formation. This review explores how blood clotting (hemostasis) and thrombosis may contribute to systemic sclerosis (SSc) and if anticoagulation therapy could help.
Area of Science:
- Rheumatology
- Hematology
- Pathophysiology
Background:
- Systemic sclerosis (SSc) is a multisystem connective tissue disease.
- Characterized by endothelial autoimmune activation, fibrosis, vasculopathy, and reduced angiogenesis.
- Endothelial barrier dysfunction leads to vascular leak and platelet activation.
Purpose of the Study:
- To review the pathophysiology of hemostasis and thrombosis in SSc.
- To investigate the potential role of these processes in SSc development.
- To explore the possible benefits of anticoagulation therapy in SSc.
Main Methods:
- Literature review focusing on hemostasis and thrombosis mechanisms in SSc.
- Analysis of endothelial activation, platelet aggregation, and coagulation cascade.
- Examination of tissue factor (TF) role in SSc-related coagulation.
Main Results:
- Endothelial injury in SSc promotes platelet adhesion and aggregation.
- Activated platelets and tissue factor contribute to thrombin generation and coagulation cascade amplification.
- These hemostatic and thrombotic processes are implicated in SSc pathophysiology.
Conclusions:
- Hemostasis and thrombosis play a significant role in the pathogenesis of systemic sclerosis.
- Understanding these mechanisms may reveal new therapeutic targets.
- Anticoagulation therapy warrants further investigation for its potential in managing SSc.
Abstract:
Systemic sclerosis is a multisystem connective tissue disease, characterized by endothelial autoimmune activation, along with tissue and vascular fibrosis leading to vasculopathy and to a progressive loss of angiogenesis. This condition further deranges the endothelial barrier favouring the opening of the endothelial junctions allowing the vascular leak in the surrounding tissues: this process may induce cell detachment which allows the contact between platelets and collagen present in the exposed subendothelial layer. Platelets first adhere to collagen via glycoprotein VI and then, immediately aggregate because of the release of von Willebrand factor which is a strong activator of platelet aggregation. Activated platelets exert their procoagulant activity, exposing on their membrane phospholipids and phosphatidylserine, enabling the adsorption of clotting factors ready to form thrombin which in turn drives the amplification of the coagulative cascade. An essential role in the activation of blood coagulation is the tissue factor (TF), which triggers blood coagulation. The TF is found abundantly in the subendothelial collagen and is also expressed by fibroblasts providing a haemostatic covering layer ready to activate coagulation when the endothelial injury occurs. The aim of this review is to focus the attention on the underlying mechanisms related to haemostasis and thrombosis pathophysiology which may have a relevant role in SSc as well as on a possible role of anticoagulation in this disease.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Vascular Spasm
Overview of the Vascular System
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

